基于T淋巴细胞PPAR-γ-核因子-κB通路探讨平喘固本膏对支气管哮喘缓解期患者的作用机制

On the Mechanism of Asthma-relieving Foundation-consolidating Ointment in the Treatment of Bronchial Asthma at Remission Stage Based on T Lymphocyte PPAR-γ-nuclear factor-κB Pathway

目的:基于T淋巴细胞PPAR-γ-核因子-κB通路探讨平喘固本膏对支气管哮喘缓解期患者的作用机制。方法:将100例支气管哮喘缓解期患者按随机数字表法分为对照组[沙美特罗替卡松粉吸入剂(舒利迭)]和治疗组[沙美特罗替卡松粉吸入剂(舒利迭)+平喘固本膏]各50例。观察两组临床疗效,对比治疗前后两组患者中医证候积分、高迁移率族蛋白B1(high mobility group protein B1,HMGB1)、环磷酸腺苷(cyclic adenosine monophosphate,cAMP)、白三烯D4(leukotriene D4,LTD4)、免疫功能、白细胞介素10(interleukin-10,IL-10)及T淋巴细胞NF-κB活化率。结果:治疗后两组患者中医证候积分、HMGB1、cAMP、LTD4、免疫功能、IL-10及T淋巴细胞NF-κB活化率均较治疗前改善,治疗组改善更明显(P<0.05)。结论:在沙美特罗替卡松粉吸入剂的基础上口服平喘固本膏可通过升高支气管哮喘患者T淋巴细胞源性IL-10水平从而抑制支气管哮喘患者T淋巴细胞NF-κB的活性及PPAR-γ-NF-κB通路。

Objective:To discuss the mechanism of asthma-relieving foundation-consolidating ointment in treating bronchial asthma(BA) at remission stage based on T lymphocyte PPAR-γ-nuclear factor-κB pathway.Methods:All 100 cases of BA at remission stage were allocated to the control group [salmeterol ticasone powder inhalation(seretide)] and the treatment group(salmeterol ticasone powder inhalation+asthma-relieving foundationconsolidating ointment) according to random number table method,with 50 cases in each group.To observe clinical effects of both groups,to compare TCM syndrome integrals,HMGB1,cAMP,LTD4,immunologic function,IL-10 and activating rate of NF-κB in T lymphocytes before and after treatment between both groups.Results:TCM syndrome integrals,HMGB1,cAMP,LTD4,immunologic function,IL-10 and activating rate of NF-κB in T lymphocytes were improved in both groups after treating compared with these before treating,the improvement of the treatment group was more notable(P<0.05).Conclusion:Asthma-relieving foundationconsolidating ointment could inhibit the activity of NF-κB in T lymphocytes and PPAR-γ-nuclear factor-κB pathway by raising the level of T lymphocyte-derived IL-10 in patients with BA at remission stage.